Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Northwestern Medicine investigators have uncovered new insights into how intercellular "glue" functions to enable ...
News-Medical.Net on MSN9h
New enzyme target could lead to breakthrough therapies for Lyme diseaseResearchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, ...
Antibodies, which recognize viruses and proteins that the body has encountered before, have long gotten most of the credit ...
Professor Im Joo Rhyu, director of the Korea University Graduate Program for Convergence & Translational Biomedicine and ...
AZoLifeSciences on MSN18h
New Insights into How B Cells Strategically Clone High-Affinity AntibodiesA vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...
Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, and most likely other tick-borne diseases as well.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback